Tadalafil Tablet
Product Images NDC 68071-3800

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3800). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3800 3)

This is retail packaging information for Tadalafil 2.5mg tablets by Care Pharmaceuticals, Inc. It includes details like lot numbers, NDC codes, manufacturing information, expiration dates, and storage instructions. The text also advises keeping the medication out of reach of children and provides a warning to consult a doctor for medical advice about side effects.*

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This text provides information on blood pressure measurements including standing and supine diastolic and systolic blood pressure readings. Additionally, it includes a section related to time in hours.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This appears to be a graph displaying the standing systolic blood pressure readings in mmHg. The graph also mentions the use of Tadalafil 20 mg and doxazosin 8 mg. It could be referring to a study or a clinical trial evaluating the effects of these medications on blood pressure.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

This text provides information about the systolic blood pressure (BP) recorded at different time points following the administration of 20 mg tadalafil and 8 mg daily doxazosin, as well as placebo and 8 mg daily doxazosin. The text mentions time points such as 08:00 and 20:00 for the administration of tadalafil and placebo. These details are relevant for evaluating the effects of these medications on systolic blood pressure.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

This text provides information about the changes in the IPSS Total Score over the duration of treatment with Tadalafil tablets (5 mg) compared to a placebo. The data shown indicates a statistically significant difference between the two treatment groups. The duration of treatment spans for up to 12 weeks.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

This text appears to show a comparison between Tadalafil tablets 5 mg and a placebo over a duration of 12 weeks. The study likely indicates a significant difference between the two groups based on a statistical analysis with a p-value of less than 0.001.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

This text provides information on the LS mean change from baseline for Tadalafil Finasteride and Placebo Finasteride, along with the least-squares treatment difference. It indicates a comparison of the treatment effects on the specified variables.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This text provides information about a study involving Tadalafil tablets at a dosage of 5mg compared to a placebo. The study results indicate a statistically significant difference with a p-value less than 0.01 over a period of 12 weeks. The graph depicts the duration of treatment in weeks.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.